| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fd15d8ebb22202b5cfe2b109cd922c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17c6c7da627b7bead7208250127b52c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-57 |
| filingDate |
2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1abe3052c1372f84bd01a0ffc6f094c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ad49a8d144c5a554ad5dcfacaafdd8f |
| publicationDate |
2014-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101446301-B1 |
| titleOfInvention |
Cxcr3/cxcl10 antagonistic compounds, process for the preparation thereof, and a pharmaceutical composition for preventing or treating bone metastases comprising the same |
| abstract |
The present invention is based on the finding that JN-2 and ION35, which are compounds of the chimokine ligand 10 (CXCL10), competitively bind to the receptor (CXCR3) of the chimokine ligand 10 (CXCL10) ≪ / RTI > In this study, we investigated the effect of chemokine ligand 10 (CXCL10), which is increased by bone metastasis of cancer cells, on osteoblast cells, which induces osteoclast differentiation by increasing RANKL expression, an important factor in osteoclast differentiation. (4T1) of the present invention was administered directly to the shinbone of the mouse, and the present compound was administered to the abdominal cavity for a certain period of time. As a result, inhibition of bone remodeling by cancer cells fixed in the bone was inhibited, And is useful for inhibiting and treating bone destruction and metabolic diseases caused by metastasized cancer cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022211420-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210039972-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102375097-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102337399-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023121022-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021066608-A1 |
| priorityDate |
2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |